KRAS and cancer: Clinical trials utilizing TgTCR targeting KRAS G12V (NCT03190941) and G12D (NCT03745326) in the context of HLA-A*11:01 and utilizing up to five personalized TgTCR (NCT03412877) are currently being carried out across a wide range of cancer indications [145].